PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 27, 2025Microorganisms0 citationsOpen Access

Macrolide-Resistant Mycoplasma pneumoniae Among Japanese Children from 2008 to 2024

View Full Paper
TOTomohiro OishiTKTsuyoshi KenriDYDaisuke Yoshioka

Key Points

  • Of the 133 isolates in 2024, 54.1% were macrolide-resistant Mycoplasma pneumoniae, highlighting a critical public health concern.
  • The predominant p1 genotype in 2024 was type 1 at 93.4%, contrasting with type 2 dominance in 2016, indicating a notable shift.
  • The A2063G mutation associated with macrolide resistance was found in 98.0% of resistant strains, showing high genetic stability.
  • The incidence of macrolide-resistant strains in Japan remains lower than in neighboring Asian countries but higher than in Europe.

Abstract

Mycoplasma pneumoniae (MP), an important pathogen that causes pneumonia among children and young adults, caused an epidemic every four years in Japan until 2016, with the next epidemic occurring eight years later in 2024. This study compared the prevalence of MP infections among Japanese children in 2024 to previous years using real-time polymerase chain reaction (PCR) and the p1 genotype determined using the PCR restriction fragment length polymorphism typing method from nasopharyngeal swab specimens. Of the 133 total isolates collected in 2024, 54.1% were macrolide-resistant MP (MRMP), with 98.0% of those containing an A2063G mutation in the 23S rRNA gene associated with macrolide resistance. This annual rate of MRMP and incidence of the A2063G mutation was similar to those in 2016. However, the dominant p1 genotype among isolates in 2024 was type 1 (93.4%), whereas type 2 was dominant in the previous epidemic. Thus, although the rate of MRMP in 2024 was similar to that in the previous epidemic year, the distribution of p1 genotypes was different. Further, the rate of MRMP was lower than neighboring Asian countries, including China and Korea, but was higher than in European countries. Therefore, it is important to continue monitoring MP infections in Japan.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Oishi et al. (2025) studied this question.

synapsesocial.com/papers/68d7be70eebfec0fc523833fhttps://doi.org/10.3390/microorganisms13102243
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Increased detection rate of macrolide-resistant Mycoplasma pneumoniae during the Mycoplasma pneumoniae epidemic in children: a multi-campus hospital retrospective study in Guangzhou, 2023–20242026
  2. 2Macrolide Resistance of Mycoplasma pneumoniae Among Children in Hangzhou: A 2024–2025 Post-Pandemic Surveillance Study2026
  3. 3Macrolide-resistant Mycoplasma pneumoniae in children: clinical features, treatment response, and outcomes in a retrospective cohort from China2026
  4. 4An outbreak of Mycoplasma pneumoniae in children after the COVID-19 pandemic, Shanghai, China, 20232024 · 44 citations
  5. 5Genomic surveillance of the pneumonia outbreak caused by Mycoplasma pneumoniae among patients in Russia from January 2024 to June 20252026